U.S. Pharmacist

U.S. Pharmacist is a monthly magazine focused on delivering the latest, reliable, and peer-reviewed clinical articles that are important for pharmacists across the country. It covers various areas of pharmacy practice, including community pharmacies, hospitals, managed care, outpatient clinics, home health care, long-term care, the pharmaceutical industry, and educational institutions. This resource is also beneficial for pharmacy technicians, students, and other healthcare professionals, as well as anyone interested in health management. Licensed pharmacists in the U.S. can earn Continuing Education credits through U.S. Pharmacist, which is provided by Postgraduate Healthcare Education, LLC, an organization accredited by the Accreditation Council for Pharmacy Education (ACPE).

National, Trade/B2B

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

#156950

United States

#52303

Health/Pharmacy

#98

Traffic sources

Monthly visitors

Articles

Older Adults Better Able to Fight Off Avian Flu?

1 week ago | uspharmacist.com | Robert Davidson

US Pharm. 2025;50(4):1. On a recent warm afternoon, my wife and I were turned away from a favorite reservoir and trail system in northwest New Jersey due to the detection of avian flu in dead or sick birds in the area. The site, the notice read, would be closed until further notice.
First-in-Class Oral Nonopioid Approved for Acute Pain

1 month ago | uspharmacist.com | Robert Davidson

US Pharm. 2025;50(3):4. Vertex Pharmaceuticals, Inc., recently announced that the FDA approved suzetrigine (Journavx), an oral, nonopioid, highly selective pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. In clinical trials, suzetrigine was shown to be an effective, well-tolerated medication without evidence of addictive potential, the manufacturer said.
Exploring Cannabis for Chronic Pain Treatment

1 month ago | uspharmacist.com | Manouchehr Saljoughian

US Pharm. 2025;50(3):46-48. Cannabis has been used as medicine worldwide for over a century. As the United States and other countries allow medical and recreational cannabis use, more people are turning to cannabis to treat pain.
How Blood Vessel Dysfunction Can Worsen Chronic Disease

2 months ago | uspharmacist.com | Robert Davidson

US Pharm. 2025;50(2):1. Researchers at Oregon Health & Science University (OHSU) have uncovered how specialized cells surrounding small blood vessels, known as perivascular cells, contribute to blood vessel dysfunction in chronic diseases such as cancer, diabetes, and fibrosis. The findings, published recently in Science Advances, could change how these diseases are treated.
How Immune Cells Also Drive Neuroinflammation in Alzheimer’s

Jan 15, 2025 | uspharmacist.com | Robert Davidson

US Pharm. 2025;50(1):1. Cleveland Clinic Genome Center researchers unraveled how microglia, specialized immune cells that respond to threats such as bacteria and viruses, also drive neuroinflammation in Alzheimer’s disease (AD). Published in Alzheimer’s & Dementia, the study integrated drug databases with real-world patient data to repurpose FDA-approved drugs to target disease-associated microglia in AD without affecting healthy microglia cells.
Advancing Ataxia Awareness

Jan 15, 2025 | uspharmacist.com | Manouchehr Saljoughian

US Pharm. 2025;50(1):23-25. Ataxia is a neurologic condition that causes loss of muscle coordination and balance, leading to abnormal muscle movements.1 It is a clinical finding rather than a specific disease and typically presents with gait abnormalities, speech changes, and irregular eye movements (nystagmus). The condition stems from dysfunction in brain areas that are responsible for movement coordination. Ataxia can be classified in two ways.
Circadian, Microbiome Changes Linked to Colorectal Cancer Growth

Dec 11, 2024 | uspharmacist.com | Robert Davidson

Research from the University of California, Irvine, demonstrates how disruption of the circadian clock, the body’s internal, 24-hour biological pacemaker, may accelerate the progression of colorectal cancer by affecting the gut microbiome and intestinal barrier function. This discovery may offer insights into prevention and treatment strategies.
Pair of Studies Shed Light on Diabetes

Nov 15, 2024 | uspharmacist.com | Robert Davidson

US Pharm. 2024;49(11):3. Two recently reported clinical studies add to the overall store of knowledge of diabetes on a molecular level, portending possible prevention and treatment advances against the ubiquitous endocrine disease. Researchers at the Jackson Laboratory (JAX) in Bar Harbor, Maine, discovered that DNA sequence changes that are known to increase a person’s risk for diabetes are linked to how well pancreatic cells handle molecular stress.
Metabolic Syndrome and Diabetes Risk

Nov 14, 2024 | uspharmacist.com | Manouchehr Saljoughian

US Pharm. 2024;49(11):10-12. Metabolic syndrome refers to the presence of a cluster of risk factors specific for developing type 2 diabetes (T2D). Individuals with metabolic syndrome have a five times greater risk of developing diabetes than the general population.
The Xylazine Public Health Emergency

Oct 17, 2024 | uspharmacist.com | Manouchehr Saljoughian

US Pharm. 2024;49(10):24-27. Xylazine is a nonnarcotic compound or tranquilizer that is used for pain and is FDA approved for use in veterinary medicine. It is also utilized for sedation and muscle relaxation in veterinary medicine, where it is often referred to as “horse anesthetic.” Xylazine is chemically known as N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine and is a clonidine analogue.